Streetbeat News

Partnerships

AAPL

GS

Apple Inc.'s shares fell in Monday's premarket due to two concerning reports. One report indicated slower sales for the iPhone 15 compared to the iPhone 14, due to competition from Huawei. Another report suggested that Goldman Sachs may withdraw from its consumer finance partnership with Apple, which could impact Apple's ambitions in the consumer finance sector.

Portfolio Pulse from Shanthi Rexaline

October 16, 2023 | 12:05 pm

FDOC

MDGS

Medigus Ltd. (NASDAQ:MDGS) announced that Revoltz Ltd., partially owned by Fuel Doctor Holdings, Inc. (OTC:FDOC), has entered an exclusive distribution agreement in the US for its advanced micro-mobility EVs with a leading distributor in the homeland security and law enforcement sector. The distributor committed to purchase a minimum of 500 units of PORTO, Revoltz's micro-mobility vehicles, in the coming year.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 11:58 am

AMRC

Ameresco, Inc. (NYSE:AMRC) has announced a large-scale energy efficiency project with Schaeffler Aerospace Canada Inc. The project, which began in April 2023, involves the installation of a new high efficiency chiller & boiler system to serve new air handling units at Schaeffler's Stratford, Ontario plant site. The project will also update the existing Building Automation System to integrate control of all of the new High-Efficiency Heating, Ventilation and Air Conditioning (HVAC) System HVAC equipment.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 11:52 am

JNPR

The North American Network Operators' Group (NANOG) has announced a partnership with Juniper Networks, making Juniper the official provider of routing solutions for NANOG's annual conferences.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 11:49 am

VIEW

View, a smart window company, has secured a $50M financing in the form of a senior secured credit facility from an investor consortium comprised of Cantor Fitzgerald, RXR, Anson, and Affinius.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 11:41 am

NOK

Nokia, BT Group, and MediaTek have successfully completed trials of 5G Reduced Capability (RedCap) technology with RedCap devices. The trial took place at BT Group’s Adastral Park site, utilizing Nokia’s AirScale RAN portfolio, EE’s 5G Standalone (SA) network, and MediaTek’s RedCap testing platform. RedCap technology simplifies 5G devices, particularly small IoT devices, and optimizes their power efficiency. BT Group is evaluating RedCap to support new 5G use cases.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 11:34 am

BNTX

BioNTech's shares are trading lower following Pfizer's decision to cut its COVID-19 vaccine and therapy sales outlook. Pfizer is a partner of BioNTech.

Portfolio Pulse from Bill Haddad

October 16, 2023 | 11:27 am

XAIR

Beyond Air has received an Innovative Technology contract from Vizient for its LungFit PH system. This contract will likely increase the accessibility and adoption of the LungFit PH system in hospitals and healthcare facilities that are members of Vizient.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 11:20 am

KKR

KKR & Co Inc and Flerie have formed a new global pharma services platform, Frontier Biosolutions, which will invest in companies focused on specialized pharmaceutical services. As an initial investment, the platform has invested in Munich-based Coriolis Pharma, a company involved in formulation research and development, analytical services, and non-GMP manufacturing of biologics and cell and gene therapy products. The investment is expected to drive Coriolis' expansion strategy in the cell and gene therapy segment and boost its range of global services.

Portfolio Pulse from Lekha Gupta

October 16, 2023 | 10:23 am

AZN

Ascentage Pharma has announced a clinical collaboration with AstraZeneca to conduct a Phase III study of Bcl-2 inhibitor Lisaftoclax in combination with BTK inhibitor Acalabrutinib in treatment-naive patients with first-line CLL/SLL. The global multi-center, randomized-controlled, open-label, pivotal Phase III confirmatory trial is designed to evaluate the efficacy and safety of the combination versus immunochemotherapy.

Portfolio Pulse from Charles Gross

October 16, 2023 | 8:52 am